SA
RPRX logo
Royalty Pharma plc(RPRX)
Closing price · checked 8:37 PM ETAbout this dataData status
$68.45▲0.73 (1.08%)
Extended:$67.65-0.80 (-1.17%)· 8:37 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Royalty Pharma plc (RPRX)

Debt to Equity

1.26×

TTM · Retrieved:

RPRX logo

RPRX Debt to Equity

Current (TTM)1.26×
RPRX Debt/Equity (1.28× → 1.26×)
High-resolution chart · PNG

What is debt to equity?

The debt-to-equity ratio compares total debt with shareholders’ equity. It describes how a company finances its assets.

Compare debt to equity

Values are from the market snapshot of .

RPRX debt to equity history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

Royalty Pharma plc Debt to Equity — Annual fiscal periods
Period endingDebt to EquityChange
1.382×+26.11%
1.0959×+16.57%
0.9401×−25.65%
1.2644×+2.93%
1.2284×+1.77%
1.2071×+18.14%
1.0217×−29.66%
1.4525×−4.74%
1.5249×+14.95%
1.3266×+3.60%
1.2805×—

Frequently asked questions: RPRX debt to equity

What is Royalty Pharma plc (RPRX)'s current debt to equity?

Royalty Pharma plc (RPRX)'s latest reported debt to equity (TTM) is 1.26× as of Nov 21, 2026. The debt-to-equity ratio compares total debt with shareholders’ equity. It describes how a company finances its assets.

How much historical debt to equity data is available for RPRX?

Stock Alarm Pro provides 11 dated annual fiscal periods observations for Royalty Pharma plc (RPRX)'s debt to equity, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare RPRX's debt to equity to peers or set an alert?

You can compare RPRX's debt to equity directly against sector peers (LLY, JNJ, ABBV, MRK) on Stock Alarm Pro, open the multi-ticker series in Chart Studio, or set real-time price and valuation alerts on RPRX delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.